Trevi’s key strengths include a strong liquidity position with low debt, a clean and cash‑rich balance sheet, and a focused strategy targeting a substantial unmet need in chronic cough. The lead asset has a differentiated mechanism of action and encouraging early clinical data, with the potential to be first approved in its core indications. Capital expenditure requirements are low, and the company has so far demonstrated the ability to raise equity capital when needed.

Major risks stem from the absence of revenue, growing operating losses, and accelerating cash burn. The business is highly dependent on ongoing access to equity markets and on the success of a single primary drug candidate. Clinical, regulatory, competitive, and reimbursement uncertainties are all significant, and shareholder dilution has already played a key role in funding operations. Large accumulated losses underline that the company has yet to prove it can turn its scientific progress into a sustainable business.

Looking ahead, Trevi’s story hinges far more on clinical and regulatory milestones than on near‑term financial metrics. If the company executes its late‑stage trials as planned and preserves its cash runway, it could reach pivotal data readouts that define its long‑term trajectory. Until then, investors should expect continued losses and negative cash flow, with the main swings in value driven by trial outcomes, regulatory feedback, and the company’s ability to maintain a strong balance sheet through thoughtful financing.